Are orange lollies effective in preventing nausea and vomiting related to dimethyl sulfoxide? A multicenter randomized trial by Gonella, S et al.
This full text was downloaded from iris - AperTO: https://iris.unito.it/
iris - AperTO
University of Turin’s Institutional Research Information System and Open Access Institutional Repository
This is the author's final version of the contribution published as:
Gonella S; Berchialla P; Bruno B; Di Giulio P.. Are orange lollies effective in
preventing nausea and vomiting related to dimethyl sulfoxide? A multicenter
randomized trial. SUPPORTIVE CARE IN CANCER. 22 (9) pp: 2417-2424.
DOI: 10.1007/s00520-014-2227-y
The publisher's version is available at:
http://link.springer.com/content/pdf/10.1007/s00520-014-2227-y
When citing, please refer to the published version.
Link to this full text:
http://hdl.handle.net/2318/155818
1 
 
Title of the paper 
Are orange lollies effective in preventing nausea and vomiting related to Dimethyl Sulfoxide? A 
multicenter randomized trial 
 
Running title 
Orange lollies efficacy in preventing nausea DMSO related  
  
Authors 
Silvia Gonella, RN, Division of Hematology, Azienda Ospedaliera Città della Salute e della Scienza 
di Torino, Torino, Italy; Paola Berchialla, Ph.D, Department of Clinical and Biological Sciences, 
University of Torino, Torino, Italy; Benedetto Bruno, M.D., Ph.D, Division of Hematology, Azienda 
Ospedaliera Città della Salute e della Scienza di Torino and Department of Molecular 
Biotechnology and Health Sciences, University of Torino, School of Medicine, Torino, Italy; Paola 
Di Giulio, MSc, RN, Department of Public Health and Microbiology, University of Torino, Torino, 
Italy.  
 
Correspondence: Silvia Gonella, RN, Division of Hematology, Azienda Ospedaliera Città della 
Salute e della Scienza di Torino, 3 Genova St., Torino, IT 10126, phone +039 0116334418, fax 
number +039 0116336507 (sgonella@cittadellasalute.to.it)   
 
2 
 
Abstract  
 
Purpose Nausea and vomiting (NV) related to DMSO affect patients undergoing auto-SCT despite 
anti-emetic measures. Orange flavoring may reduce gastrointestinal symptoms.  
Methods A multicenter, randomized, three-arm, open-label trial in four Italian large bone marrow 
transplant centers was conducted to assess the effectiveness of orange aroma in preventing NV 
related to DMSO. Patients were randomized to orange ice lollies, Non-citrus ice lollies and routine 
treatment (deep breaths) during reinfusion. Data on NV were collected up to 5 days after infusion. 
Sixty-nine/98 patients  were randomized: 23 to orange, 21 to Non-citrus ice lollies and 25 to routine 
treatment.  
Results Although in the 48 hours after transplantation no differences were observed in controlled 
nausea (Numeric Rating Scale 0-100 (NRS) ≤25) or vomiting, significantly fewer patients had no 
episodes of vomiting, no anti-emetic rescue therapy and no nausea (NRS <5) in the deep breath vs 
lollies groups (p = 0.017).  The intensity of nausea over time differed significantly between ice 
lollies vs routine care (p =0.001) groups, but not between the orange and Non-citrus groups (p = 
0.428).  
Conclusion The vasoconstrictive action of ice may prevent NV related to DMSO in the acute phase 
and reduce the need for rescue anti-emetic therapy. Ice lollies offer a simple, non-invasive and 
economic means for relieving nausea and vomiting related to this preservative. 
 
Keywords Nausea • Vomiting • Hematopoietic stem cell transplantation • Cryopreservation • 
Dimethyl Sulfoxide • Aromatherapy 
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Introduction 
Hematopoietic stem cell transplantation (HSCT) is standard treatment for many patients with 
congenital or acquired disorders of the hematopoietic system or with chemo-, radio- or immuno-
sensitive malignancies [1]. World-wide, 50 417 HSCTs were done in 2006, 21 516 allogeneic (43%) 
and 28 901 autologous (57%) [1]. 
 For auto-SCT, hematopoietic stem cells (CD34 +) are slowly frozen and stored in liquid 
nitrogen at -196°C with DMSO, that reduces cellular dehydration and osmotic stress [2]. Reinfusion 
may have several side effects such as hemolysis, anaphylactic reactions, kidney failure, high 
systolic and diastolic blood pressure, bradycardia. However,  gastrointestinal problems are the most 
frequent, particularly nausea and vomiting (NV), partly related to the characteristic garlic-like 
breath due to pulmonary excretion of  the cryopreservative [3, 4, 5, 6]. DMSO and its metabolites 
(dimethylsulfone and dimethylsulfide), are excreted over the 24 hours after infusion, through urine, 
skin and breathing [3]. The toxicity is proportional to the concentration and amount of DMSO [7] 
and increases with the number of bags and of cells harvested and with the patient’s weight [2, 4, 6, 
8]. A 10% solution is generally used [2, 3]; the 5% solution with lower incidence of side effects is 
not recommended for lengthy storage since its safety has been assessed only over a few months [9, 
10]. 
 Dimethyl sulfoxide may activate the vomiting center through the CTZ as soon as the agent is 
detected in the blood. This sensation may be compounded as it passes directly into the saliva and is 
then tasted and smelled upon entering the oral and nasal cavity [13]. Previous studies [14] showed 
that an unpleasant odor can be masked by a pleasant one presumably through lateral inhibitory 
connections in the local neuronal circuit of the olfactory bulb [18,19]. The incidence of nausea with 
DMSO may range between 50% and 80% [2]; older patients are less affected [6]. This variability is 
probably related to the individual threshold and to the emetogenic property of the conditioning 
regimen.  No drug seems to relieve NV associated with DMSO [11] with its negative impact on 
quality of life and on the risk of anorexia, dehydration and electrolyte imbalance, up to renal failure 
[12]. Nausea, even mild, may negatively affect the quality of life in 25% of patients [12]. 
 The smell and flavor of orange may reduce the patient’s perception of its odor [5, 6] and thus 
NV (an unpleasant odor can be masked by a pleasant one [13, 14]) although studies have given 
conflicting results. This suggested the hypothesis that DMSO-evoked activity map (odor map) 
might be inhibited by activation of mitral cells in the neighboring orange-responsive clusters. 
Potter’s three-arm trial [6] showed that orange slices and aromatherapy with orange fragrance 
during the reinfusion of autologous stem cells were more effective than deep breathing - the “gold 
standard” - for reducing nausea, while Ndao’s double-blind, placebo-controlled trial [11] found no 
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benefit of respiratory aromatherapy with bergamot essential oil when added to standard supportive 
care. No studies explored the length of this inhibition, however we might suppose that it is longer 
than the effective masking-stimulus since Takahashi et al. [14] noted that, in many mitral-tufted 
cells, responses to odorants lasted for long period even after cessation of the odor stimulation. 
 The aims of the study were to assess the effectiveness of orange aroma in preventing DMSO-
related NV and to measure the incidence of NV and need for anti-emetic rescue therapy in patients 
undergoing auto-SCT.  
 
Methods 
Study design and clinical setting 
In this experimental, three-arm, open-label trial, patients undergoing auto-SCT were recruited in 
four large bone marrow transplant centers with more than 20 autologous transplantation/year in 
Piedmont (northern Italy) between June 2012 and January 2013. The study was approved by the 
ethics committees. All patients provided written informed consent. 
 
Patients 
Ninety-eight patients were consecutively evaluated at entry and 69 (70%) were recruited (Figure 1). 
Patients older than 18 years, able to use the Numerical Rating Scale (NRS) 0-100 and to give 
consent were included.  Patients with known or suspected allergy to (or dislike of) oranges or ice 
lollies, expected to require three or more bags of autologous stem cells, nausea or vomiting not 
controlled at the end of the conditioning phase, dental pain or hypersensitivity to cold were 
excluded. 
 
Study procedures 
Patients were randomized to three groups by randomization in blocks with step 6 (ratio 1:1:1) 
stratified by center using the software randomization.com [20]. Treatment codes in sealed opaque 
envelopes. 
 Stem cells were stored in liquid nitrogen at -196°C with 10% DMSO. Bags were thawed at 
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37°C and reinfusion started within a few minutes. All patients received  premedication with steroids 
and during reinfusion were encouraged to breathe deeply (inhaling through the nose and exhaling 
through the mouth to expel DMSO). One group was randomized to orange ice lollies during 
reinfusion (Orange group), another to Non-citrus lollies (Non-citrus group) and the third group to 
deep breaths (Only-breathing group). Lollies sucking started and ended with infusion. Ice lollies 
were chosen in place of other modalities (i.e orange in slices) to standardize the intervention and 
guarantee the administration of controlled quantity of orange aroma. Patients were given two ice 
lollies for each bag (the reinfusion lasts 10-15 min per bag and it takes 5-8 minutes to finish an ice 
lolly) and they were free to ask for more. In the pilot study the median consumption was 1.5 ice 
lollies [range 1-3] per bag. A nurse was present throughout the reinfusion. 
 We used commercial ice lollies with a 13-20% concentration of aroma and all Non-citrus 
fragrances except aniseed, which may be emetic [21]. Ice lollies were provided by the catering 
company or purchased by patients. 
 The following information was collected: (1) Patients’ main demographic and clinical 
characteristics, underlying disease, previous transplantation (clinical records); recurrent headache (≥ 
2 episodes/week), history, previous chemotherapy-induced nausea and vomiting, motion or morning 
sickness (interview); self-administered Zung Self-Rating Anxiety Scale (SAS) [22]. This consists of 
20 items on a four-point scale (from a little to most of the time). The SAS score was converted into 
an Anxiety index: scores ≥ 45 indicate anxiety; (2) Treatment: conditioning regimen, chemotherapy 
cycle, premedication and anti-emetic prophylaxis (clinical records); number of bags and number of 
ice lollies sucked during the reinfusion; (3) Side effects: nausea (NRS 0-100), vomiting (number of 
episodes), and vital signs before and after reinfusion; any adverse reactions during the reinfusion. 
 The emetogenic potential of conditioning cycles was evaluated with the Hesketh score and was 
comparable, except for melphalan 100 mg/m2 [23].  
 From the transplantation day until day +5 each patient self reported every 4-hour: nausea 
intensity (NRS 0-100); vomiting and retching episodes; anti-emetic rescue therapy. The median 
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intensity of nausea was measured over 24 hours; the number of episodes of vomiting and retching 
and of doses of anti-emetic rescue therapy were recorded from the end of reinfusion. 
In each ward an experienced nurse was instructed for data collection. Consultancy was available 
throughout the data collection period. 
 Nausea was considered absent if <5, controlled between 5 and 25 and not controlled if >25 
[12]. Vomiting and retching were recorded separately and considered controlled if ≤ 2 episodes 
(vomiting and retching) in the 24 hours before reinfusion [12] and ≤ 1 episode during reinfusion. 
 
Study outcomes 
Primary 
 Proportion of patients with controlled nausea (NRS ≤25) or vomiting  
Secondary 
 Proportion of patients with  
1. no nausea (NRS <5) or vomiting; 
2. complete protection (no vomiting, no anti-emetic rescue therapy and controlled 
nausea); 
3. total control (no vomiting, no anti-emetic rescue therapy and no nausea). 
After reinfusion patients were assessed in up to 48 hours (early period), to account 
for possible delayed effects of DMSO, and in the total period (0-120 hours). Late 
phase refers to 48-120 hours after auto-SCT.  
 
Statistical analysis 
Continuous variables were expressed as median and interquartile ranges and were compared 
between groups using the Kruskal-Wallis test. Categorical variables were summarized as sums and 
percentages and the χ2 test with Yates’ correction (or Fisher’s  exact test) was used for comparisons. 
Correlation was assessed using the Spearman coefficient. 
7 
 
 A generalized least-square regression model was used to ascertain whether the interaction 
between groups and time with respect to nausea intensity was significant [24]. A correlation 
structure was specified to account for repeated measures over time (24, 48, 72, 96 and 120 hours 
after reinfusion) on the same patient. A continuous-time autoregressive of order 1 (CAR1) 
correlation structure resulted in the best model fit, based on Akaike Information Criterion (AIC) 
values. Age, sex and number of stem cell bags infused were entered into the model. The linear 
relationship of nausea intensity over time was assessed using restricted cubic splines and tested with 
a Wald chi-square test. 
 The data were analyzed with R version 2.15 [25]. All p values are two-sided and  significance 
less than 0.05 was considered significant. Analyses were performed by intention-to-treat.  
 
Sample size  
In the pilot study all patients in Orange lollies had controlled nausea or vomiting, 83% in Non-citrus 
lollies and 50% in only-breathing; with 23 patients in each group we can show, with 90% power, a 
15% difference in the proportion with controlled nausea or vomiting 48 hours from auto-SCT, at a 
two-sided α level of 0.05 with Bonferroni correction for multiple comparisons. 
 
Results 
Over 60% of patients were males and almost half were conditioned with melphalan 200 mg/m2.  
None had electrolyte imbalance or had been treated with radiotherapy (Table 1). 
 The number of patients with previous auto-SCT differed significantly among groups (P=0.005), 
but the incidence of not controlled nausea or vomiting in the 48 hours post-transplant was similar in 
patients at the first vs second reinfusion (7.7 vs. 13.3%, P =0.458). 
 Premedication and anti-emetic prophylaxis before reinfusion were given at standard doses; six 
patients received a 3-drug premedication (3 both in lollies and Only-breathing group) and ten a 
multidrug prophylaxis (6 in lollies and 7 in Only-breathing group). No patients were administered 
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drugs during infusion (table 2).  
 Sixteen patients (70%) in the Orange and 15 (71%) in the Non-citrus group had only one bag in 
10 percent DMSO-cryopreserved PBSCs vs 21 (84%) of the Only-breathing group. Infusion rate 
ranged between 20 to 50 ml per minute throughout all the groups and reinfusion lasted about 12 
minutes with one bag, 28 with two. The median consumption of ice lollies was 1.5 [range 1-2.5] in 
the Orange group and 1 [1-1.5] in the Non-citrus group.  
 Overall, vital signs remained stable during reinfusion, except for a slight increase in systolic 
blood pressure in the Orange group. Four patients reported an adverse event: a hypotensive crisis 
(Non-citrus and Only-breathing groups) and an episode of bradycardia (Orange and Non-citrus 
groups). 
 
Nausea before, during and after reinfusion 
Sixteen patients (80%) in the Orange and 14 (78%) in the Non-citrus group reported no nausea 
during reinfusion vs 15 (71%) of the Only-breathing group. The numbers of patients with 
uncontrolled nausea during transplantation were comparable, though slightly lower in the ice lollies 
groups. At the end of reinfusion 20 Only-breathing patients (83%) had no or controlled nausea vs 20 
(95%) in the Non-citrus and 21 (91%) in the Orange group. In all, 23 patients (30%) did not report 
nausea. 
 In the first 48 hours, over 90% of ice lollies patients (21 (91%) in the Orange and 20 (95%) in 
the Non-Citrus group) had no or controlled nausea, compared to 76% (19) of the Only-breathing 
group. About 30% of patients randomized to ice lollies (8-35% in the Orange and 6-29%, in the 
Non-Citrus group) reported nausea ≥ 5 compared to over 60% (16) of  the Only-breathing group. 
 Forty-eigth hours after infusion, 45 patients (65%) reported nausea which was uncontrolled in 9 
(36%) Only-breathing, 7 (30%) Orange and 3 (14%) Non-citrus patients. Overall 24 had nausea > 
25 at least once in the five days after transplantation. Generally the nausea started to increase on the 
third day after reinfusion with a peak between 72 and 96 hours, decreasing on the fifth day. The 
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pattern for vomiting was similar. A borderline significant interaction (P=0.057) emerged between 
treatment and time: nausea remained almost unchanged in Only-breathing patients; while initially 
lower in the ice lollies groups raised over the next few days, up to the level of the Only-breathing 
group on day 5. 
 Longitudinal regression analyses including treatment, age, sex, number of bags and hours from 
transplant showed a significant difference between the three treatments (P=0.0003), as well as an 
average increase of 3.8 points in nausea intensity every 24 hours regardless of the treatment; female 
sex was a risk factor for nausea. Nausea intensity over time was significantly different between the 
ice lollies and Only-breathing (P=0.001), but not between Orange and Non-citrus groups (P=0.428). 
 The longitudinal regression model showed a significant reduction of nausea with age, and a rise 
with the number of bags infused. In the first 48 hours after transplantation median nausea was 2.1 
[0-11.5] if one bag was infused and 10.4 [0-18.1] if two.  No correlation was observed between 
weight and nausea control in the acute or delayed phase. 
 
Vomiting before, during and after reinfusion 
About a quarter of the patients (16, 23%) had at least one vomiting episode in the 24 hours before 
the transplant. 
 During transplantation six patients vomited in the Orange group and four in the other groups. 
 Similarly, in the first 48 hours almost all  ice lollies patients had no or controlled vomiting 
(22/23 Orange and 20/21 Non-citrus group) vs 15/25 (60%) in the Only-breathing group. 
 Throughout the five-day observation period about half the patients who ate lollies reported at 
least one episode of vomiting (13 Orange and 11 Non-citrus group) compared to 80% (20) of  the 
Only-breathing group. 
 
Effectiveness of orange ice lollies   
No significant difference in the primary endpoint (controlled nausea or vomiting) during reinfusion 
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(P=1.000) or in the following 48 hours (P=0.090) was observed between groups, although in the 
two days post-transplant these symptoms were still controlled only in the ice lollies patients (93% 
controlled nausea and 96% controlled vomiting) vs 76% controlled nausea and 60% controlled 
vomiting in the Only-breathing group. Significant differences were observed for all secondary 
endpoints (Table 3). During the first 48 hours significantly fewer patients had no nausea or vomiting 
in the Only-breathing group vs ice lollies (p = .002). In fact, patients with complete protection were 
more than double in the ice lollies group compared to Only-breathing (P =0.003) and the pattern 
was similar for total control (P =0.017). 
 
Antiemetic rescue therapy 
Twenty-three (30%) patients required anti-emetic rescue therapy but in the ice lollies groups from 
the third day and in the Only-breathing group already in the first 48 hours (Table 3). During the five 
days, five patients in the Orange, six in the Non-citrus and 12 in the Only-breathing groups required 
rescue therapy and respectively 10, 14 and 33 doses were given. 
 
Discussion 
This is the first study that assessed the effect of ice lollies in preventing DMSO-related NV in 
patients undergoing auto-SCT. Although we found no differences in controlled nausea or vomiting 
in the 48 hours post-transplant and though considering the delayed emetogenic effect of melphalan, 
over 90% of patients randomized to ice lollies had controlled nausea and almost all controlled 
vomiting (≤ 2 episodes), compared to respectively 76% and 60% in the Only-breathing group. The 
advantage was observable in the first 48 hours [No nausea or vomiting in 89% ice lollies vs 52% 
Only-breathing patients (P=0.002)]; furthermore, 57% in the lollies groups had total control 
compared to 24% Only breathing (P=0.017).  
 These findings suggest that ice lollies may have an anti-emetic effect and a larger sample would 
probably have shown statistically significant differences in the primary endpoint. 
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 The effect of ice lollies on NV mechanisms seems related to the vasoconstriction or reduction 
of taste perception due to cold, more than to the orange aroma. In fact the proportions of patients 
with complete protection and total control were similar in the lollies groups; the differences for 
nausea intensity disappeared after adjustment for treatment, age, sex, number of bags and hours 
from transplant (P=0.428), but remained when comparing with the Only-breathing group 
(P=0.001).   The lack of effect on reduction of nausea from inhaled aromatherapy was already 
shown in adolescents undergoing auto-SCT [11]. 
 Gastrointestinal symptoms continue to be a problem in the first 48 hours despite anti-emetic 
prophylaxis: more than 40% of patients reported nausea, and 23 vomiting, in 16 cases despite no or 
controlled nausea, suggesting that the two symptoms are different, although related. In the first 48 
hours only one patient in the ice lollies groups required anti-emetic rescue vs 11 in the Only-
breathing group; the advantage was maintained despite comparable levels of delayed nausea.  
 After 48 hours symptom control was worse: more than 65% of patients reported nausea,  not 
controlled in 42%, and about 60% had at least one episode of vomiting (80% in the Only-breathing 
group). The intensity of nausea increased with time (borderline significant interaction (P=0.057)): 
however, it cannot be attributed to DMSO, whose half-life is only 24-36 hours [2, 3], but, more 
likely to the mucositis whose preliminary symptoms are nausea and abdominal cramps [26]. Its 
incidence ranges between 75% and 85% and it usually arises 3 to 5 days after transplant [22, 23, 24, 
25]. The delayed nausea may depend on P-dependent (Undecapeptide tachykinin acting as a sensory 
neurotransmitter in the central nervous system and as a local hormone in the gastrointestinal tract 
,involved in pain and vomiting) mechanism and therefore it might be caused by cytotoxic therapy-
induced mucosal damage (CIMD) [26]. Thus the nausea is initially linked to the cryopreservative 
and later to gastrointestinal mucosal damage [26]. 
  The intensity of nausea increased with the number of bags infused [7]; female sex was 
confirmed as an independent risk factor for nausea (P=0.028) and a likely predictor of Mucositis 
[27, 28]. 
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 Since the amount of stem cells needed (and the number of bags) increases with body weight, a 
parallel increase in nausea was expected in patients infused 2 bags: differently from Potter’s study 
[6], we found no correlation. However, our population was hardly comparable to Potter’s as only 
four patients (6%) weighed more than 90 kg compared to 27 (45%) in the American study.  
 
Strengths and limitations 
The central randomization prevented a selection bias, and stratification by center avoided a center 
effect. A major strength of the study is the generalization of the results to Italian patients undergoing 
auto-SCT, since patients’ main demographic and clinical characteristics and chemotherapy cycles 
are comparable across centres.  
 No data was lost due to the excellent patients’ collaboration and intervention (administration of 
ice lollies) was more comparable than in previous studies [6]. The three-arm design allowed to 
assess whether the efficacy of the intervention was related to the vasoconstrictive action of ice or 
aroma.  
 The study was limited by its small sample size and the predominance of male patients, although 
the prevalence of auto-SCT is considerably higher in men [29, 30]. Moreover, we did not record the 
total dose of DMSO in mg/kg which can affect nausea and vomiting; however, 31 ice lollies 
patients (70%) (16 (70%) Orange and 15 (71%) Non-Citrus) had only one bag in DMSO-
cryopreserved PBSCs vs 21 (84%) in the Only breathing group, thus the latter were overall less 
exposed to DMSO.  
Conclusion 
Although no differences were observed for controlled nausea or vomiting, the results suggest the 
potential efficacy of ice in raising the proportion of patients with no nausea or vomiting due to 
DMSO and in reducing the need for anti-emetic rescue therapy. However, larger samples are needed 
to confirm whether the effect was due to the vasoconstrictive action of ice rather than the aroma 
itself, testing flavors in different forms (ice lollies, candies or lollipops). 
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 The need of anti-emetic prophylaxis of conditioning cycles should be revised since half the 
patients came to the transplant day with uncontrolled nausea or vomiting. 
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Table 1 Patients’ main baseline characteristics  
 
Orange 
(n = 23) 
Non-citrus  
(n = 21) 
Only deep 
breathing 
(n = 25) 
P value 
Male (n/%) 
Age years (median; IQR) 
Weight kg (median; IQR) 
Education (n) 
   Elementary school 
   Junior school 
   High school 
   University  
History (n) 
Smoking 
Hypertension 
Previous CINV 
Opioid therapy in progress 
Recurrent headache 
Anxiety 
Motion sickness 
Morning sickness 
Diabetes 
Ex-alcohol drinker 
Dyslipidemia 
Renal failure 
Past drug addiction 
Diagnosis (n) 
MM/LNH/LAM/L. Plasmacellular/LH 
M. Waldestrom/L.Burkitt/reticulosarcoma 
Previous transplantation n (%) 
Chemotherapy cycles (n) 
Mel 100/Mel 200/FEAM/BEAM/M-VD/  
Bu-Cy/Ara-C+Idarubicina/D-PACE 
Myeloablative conditioning n (%) 
 
17 (74) 
60 [52-64] 
70 [62-84] 
 
3 
8 
7 
5 
 
9 
9 
9 
5 
4 
3 
2 
1 
1 
- 
1 
2 
1 
 
19/2/1/1 
 
12 (52) 
 
6/12/3/-/- 
1/-/1 
 
16 (70) 
12 (57) 
58 [53-62] 
74 [64-83] 
 
- 
7 
7 
7 
 
8 
8 
3 
3 
4 
3 
2 
1 
1 
3 
1 
- 
1 
 
12/5/1/-/1 
-/1/1 
3 (14) 
 
4/7/8/-/1 
1 
 
15 (71) 
14 (56) 
55 [49-64] 
69 [62-79] 
 
2 
6 
14 
3 
 
9 
6 
10 
2 
2 
4 
4 
5 
3 
1 
1 
1 
- 
 
14/3/2/4/1 
1 
15 (60) 
 
3/13/3/1/3 
1/1 
 
19 (76) 
0.371 
0.325 
0.719 
0.135 
 
 
 
 
 
0.974 
0. 341 
0.144 
0.401 
0.507 
0.958 
0.687 
0.124 
0.517 
0.115 
0.684 
0.161 
0.115 
0.707 
 
 
0.005 
0.297 
 
 
 
0.712 
     
Abbreviations: BEAM, bendamustine-etoposide-cytarabine-melphalan; Bu-Cy busulfan-cyclophosphamide; CINV, 
chemotherapy-induced nausea and vomiting; D-PACE, dexamethasone-cisplatin-adriblastin-cyclophosphamide-
etoposide; FEAM, fotemustine-etoposide-cytarabine-melphalan; LAM, acute myeloid leukemia; LH, Hodgkin’s 
lymphoma; NHL, Non-Hodgkin’s lymphoma; Mel 100, melphalan 100 mg/m2; Mel 200, melphalan 200 mg/m2; MM, 
multiple myeloma; M-VD, velcade-melphalan-dexamethasone 
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Table 2 Reinfusion premedication and anti-emetic prophylaxis  
 
 Orange 
(n = 23) 
Non-citrus 
(n = 21) 
Only  breathing 
(n = 25) 
Premedication (n)a 
  Methylprednisolone 125 mg + chlorphenamine 10 mg 
  Hydrocortisone 200 mg + chlorphenamine 10 mg 
  Hydroxyzine 25 mg 
 
19 
5 
1 
 
17 
5 
- 
 
20 
6 
2 
Antiemetic prophylaxis (n)a 
Ondansetron 
Metoclopramide 
Aprepitant 
Chlorphenamine 
Alizapride 
Dexamethasone 
Granisetron 
 
20 
4 
3 
1 
1 
- 
- 
 
19 
3 
1 
- 
- 
- 
- 
 
23 
2 
3 
2 
- 
1 
1 
a The sum is greater than the total because some patients received multidrug treatment 
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Table 3 Effectiveness of interventions during auto-SCT and in the subsequent 48 hours  
 
 DURING REINFUSION IN THE FOLLOWING 48 HOURS 
 Ice lolly Only 
breathing 
(n = 25) 
(n/%) 
P 
valuea 
Ice lolly Only 
breathing 
(n = 25) 
(n/%) 
P 
valuea 
  
Orange 
(n = 23) 
 (n/%) 
Non-
citrus 
(n = 21) 
(n/%) 
Orange 
(n = 23) 
(n/%) 
Non-
citrus 
(n = 21) 
(n/%) 
  
a. Controlled nausea or 
vomiting 
21 (91.3) 20 (95.2) 23(92) 1.000 22 (95.7) 20 (95.2) 20 (80) 0.090 
b. No nausea or vomiting 18 (78.3)  18 (85.7)  22 (88) 0.734 21 (91.3) 18 (85.7) 13 (52) 0.002 
c. Anti-emetic rescue therapy - - 3 (12) 0.044 5 (21.7) 6 (28.6) 12 (48) 0.092 
d. Complete protection 17  (74) 14 (70)c 16 (66.7)d 0.776 17 (73.9) 16 (76.2) 9 (36) 0.003 
e. Total control 16 (69.6) 12 (60)c 13 (54.2)d  0.489 12 (52.2) 13 (61.9) 6 (24) 0.017 
f. Time from infusion of stem 
cells to first emesisb 
- - - - 
0-24 h  
2 (8.7) 
0-24 h  
2 (9.5) 
0-24 h  
9 (35) 
0.010 
a Ice lolly vs. Breathing    
b Calculated on the number of cases not events 
c 20 patients       
d 24 patients 
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Assessed for eligibility (98) 
Randomized (69) 
Excluded (23, 23.5%) 
Exclusion criteria  
- Uncontrolled nausea (10) 
- Not able to use NRS scale (4) 
- Bags  ≥ 3 (3) 
- Uncontrolled vomiting (1) 
- Two or more criteria (4) 
- Previous stem cell transplantation (1) 
Drop out (4) 
-Vomiting onset (3) 
-Uncontrolled nausea (1) 
Drop out (4) 
-Vomiting onset (3) 
-Uncontrolled nausea (1) 
 
Drop out (0) 
 
Deep breathing + 
orange ice lolly (23) 
Deep breathing + non- 
citrus ice lolly (21) 
Only deep breathing  
(25) 
Analyzed (23) Analyzed (21) Analyzed (25) 
Eligible (75) 
No consent (6) 
Figure 1 Screening, enrolment and randomization 
